DTIL Precision BioSciences
- 9.4100
- -0.4800-4.85%
Precision BioSciences News
Precision BioSciences Announces Its Addition to the Russell Microcap Index
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene
Precision BioSciences Showcases ARCUS Platform at Mitochondrial Medicine 2024
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, inclu
Precision BioSciences to Present Preclinical Data on Hepatitis B Treatment at EASL Congress
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies, today announced that the company w
Express News | Precision BioSciences Inc: Ind and/or Cta on-Track for Submission in 2024
Express News | Precision BioSciences Inc: Pbgene-Hbv Was Well Tolerated Across Multiple Administrations With No off-Target Editing Observed
Express News | Precision BioSciences Presents New Preclinical Safety Data for Pbgene-Hbv Clinical Candidate at the European Association for the Study of the Liver Congress
Precision BioSciences to Participate in Upcoming June Investor Conferences
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene
Buy Rating on Precision BioSciences: Leading the Way in Gene Editing for Chronic Hepatitis B
Buy Rating Affirmed for Precision BioSciences on Strong Pipeline and Market Potential
Express News | Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Express News | HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
Precision BioSciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 395.87% HC Wainwright & Co. → $60 Reiterates Buy → Buy 04/30/2024 57.02% Guggenheim → $19 Initi
Analysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL) and Adicet Bio (ACET)
Maintaining Hold on Precision BioSciences Pending Clinical Data and Strategic Reassessments
Buy Rating Affirmed for Precision BioSciences on Advancing Gene Editing Pipeline and Strong Financials
Quarterly Results Takes Precision BioSciences Higher
Precision BioSciences Reports Profit From Cont. Ops. In Q1
Precision BioSciences | 10-Q: Quarterly report
Express News | Precision BioSciences Inc - Expected Runway Into H2 2026
Precision BioSciences Q1 EPS $1.70 Beats $(1.91) Estimate, Sales $17.58M Beat $6.02M Estimate
Precision BioSciences (NASDAQ:DTIL) reported quarterly earnings of $1.70 per share which beat the analyst consensus estimate of $(1.91) by 189.01 percent. This is a 124.64 percent increase over losses
Analysis
Price Target
No Data
